Early stage opportunity ForCast Orthopedics is an early stage device company focused on intraarticular antibiotic delivery to treat periprosthetic joint and spinal infections. This presents a regulatory and sales cycle with high potential upside if the products progress toward FDA clearance.

Clinical unmet need Current treatments for PJI and related infections rely on methods that fail to eradicate biofilms. The company aims to automate IA I therapy to improve outcomes, offering a compelling value proposition to surgeons seeking better infection control and reduced reoperations.

Strategic partnerships With a founder team including a leading orthopedic surgeon and med-tech executive, there is potential to pursue collaborations with large OEMs and academic centers for clinical validation, early access programs, and co-development avenues.

Regulatory path Products ACK Spacer and RIDDS are not yet FDA cleared or sold. Targeting partnerships with established regulators and early pilot deployments at clinical sites could accelerate validation milestones and marketing readiness.

Market positioning Benchmarking against large peers (Exactech, Arthrex, Stryker, Medtronic) suggests focus on niche infection control solutions with scalable clinical adoption. Emphasize cost reduction, shorter hospital stays, and decreased patient morbidity to drive conversations with hospital procurement and payers.